Schwelm

Researchers are conducting a global study to understand the impact of moderate to severe alopecia areata (AA), non-segmental vitiligo (NSV), and hidradenitis suppurativa (HS) on adolescents and adults. This study aims to assess the burden these conditions place on patients' quality of life and daily functioning in a large real-world population. The study involves participants diagnosed by a physician with one of the three conditions: AA, NSV, or HS. There are no interventional treatments or medications being tested in this study, as it is observational in nature. Data collection focuses on patient-reported outcomes and measures that evaluate disease severity and its effects. Participants will complete various questionnaires and assessments related to their condition, such as the Alopecia Areata Symptom Impact Scale (AASIS) for AA, the Severity of Alopecia Tool (SALT) for scalp hair loss in AA, the Facial Vitiligo Area Scoring Index (F-VASI) and Vitiligo Quality of Life Score (VitiQoL) for vitiligo, and the Dermatology Life Quality Index (DLQI) and International Hidradenitis Suppurativa Severity Scoring System (IHS4) for HS. These tools help researchers understand how symptoms affect quality of life and disease severity. The study collects information up to the day of the study visit.

Psoriasis is a chronic inflammatory disease that causes thick, red, and white scaly patches on the skin. This research evaluates how treatment with risankizumab affects the quality of life for adults with moderate to severe plaque psoriasis in real-world clinical settings. The study involves about 700 participants who are prescribed risankizumab by their doctors following local guidelines. Participants will receive risankizumab as directed by their physicians according to routine clinical practice and local prescribing information. There are no additional treatments or interventions beyond what is normally prescribed. The study follows participants for up to 2.5 years, with regular visits at hospitals or clinics based on their usual care schedules. During the study, participants will attend routine visits without extra burden. Researchers will monitor changes in quality of life using the Dermatology Life Quality Index (DLQI) at 12 months and observe the long-term impact of risankizumab treatment. Safety and treatment adherence will also be tracked throughout the study period.